Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide and CagriSema for weight management in children and adolescents with overweight or obesity
2023-509176-42-00Phase 4Authorised
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 26
01
Overview
Phase 4, randomised trial of cagrilintide and semaglutide in obesity and Overweight (4 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change in body mass index. Planned start Aug 2026; status: authorised.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2023-509176-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509176-42-00.